Stryker (SYK) Earnings Date & Reports

Key Takeaways

• Adjusted earnings per share (EPS) came in at $3.69, surpassing the consensus estimate of $3.49 by $0.20 and reflecting a 17.9% increase from $3.13 in the same quarter last year.
• Revenue reached $6.59 billion, edging past analyst expectations of $6.58 billion and representing year-over-year growth of 9.4%.
• Organic net sales growth was 9.0%, driven by strong unit volume across both the MedSurg and Neurotechnology segment and the Orthopaedics segment.
• Full-year 2026 guidance was narrowed: organic sales growth is now projected at 8.3% to 9.3%, while adjusted EPS is expected between $14.95 and $15.10.
• Despite the beats, shares fell approximately 9% in after-hours trading, suggesting investors were focused on the limited guidance upgrade and the second-half execution ramp.
• The quarter marked a meaningful recovery from the March 2026 cybersecurity incident that disrupted first-quarter operations and delayed revenue recognition.

Earnings Context and Why It Matters

Stryker's second-quarter 2026 results arrived at a pivotal moment. The company entered this reporting cycle under heightened investor scrutiny following a March cyberattack that disrupted its Microsoft systems, delayed product shipments, and contributed to a significant first-quarter earnings miss. With Q1 adjusted EPS falling 12.75% short of consensus, the market was eager to see whether Stryker could recapture momentum. The Q2 report was therefore viewed as a critical litmus test for the company's operational resilience and its ability to recover deferred revenue. As one of the largest medical technology companies in the world, Stryker's performance also served as a broader read on procedural demand trends, hospital capital spending, and the pace of robotic surgery adoption across the medtech industry.

Reported Results

Stryker reported second-quarter 2026 net sales of $6.59 billion, an increase of 9.4% compared to $6.02 billion in the prior-year period. Organic net sales — which exclude the impact of foreign currency and acquisitions — rose 9.0%, fueled entirely by higher unit volume. The MedSurg and Neurotechnology segment generated $3.63 billion in revenue, up 9.7% year over year, with organic growth of 9.2% led by a 13.4% surge in the Medical business, which includes patient handling and emergency care equipment. Orthopaedics delivered $2.96 billion in sales, up 9.1%, with organic growth of 8.6%. Trauma and extremities led the orthopaedic sub-segments at 11.9% growth, while knee implants rose 8.4% and hips grew 2.9%.

On the bottom line, reported net earnings were $1.28 billion, or $3.30 per diluted share, compared to $884 million, or $2.29 per share, a year ago. Adjusted EPS — which strips out one-time items — climbed 17.9% to $3.69, exceeding the FactSet consensus of $3.49. Adjusted gross margin expanded 60 basis points to 66.0%, and adjusted operating margin rose 170 basis points to 27.4%, helped by a net tariff benefit, favorable business mix, and cost discipline.

Management also narrowed full-year 2026 guidance. Organic net sales growth is now expected in the range of 8.3% to 9.3%, tightened from the prior 8.0% to 9.5%. Adjusted EPS guidance moved to $14.95 to $15.10, raising the lower end from the previous $14.90. The update signaled confidence but left limited room for upside relative to consensus, which stood at $14.97.

AI Screener

For investors looking to identify opportunities in the medical technology space and beyond, Tickeron's AI Screener offers a powerful, AI-driven platform designed to streamline stock and ETF discovery. The tool allows users to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. By surfacing breakout candidates, trending stocks, and high-conviction trade ideas more efficiently than manual screening, the AI Screener helps traders and investors stay ahead of market movements. Whether monitoring earnings season or scanning for technical setups across the healthcare sector, the AI Screener can help refine your research process with speed and precision.

Market Reaction and Investor Sentiment

Stryker shares closed the regular trading session on July 30 at $348.37, down roughly 1.1% on the day. However, the stock dropped approximately 9% in after-hours trading, slipping to around $316, following the earnings release and conference call. The sharp selloff — despite beats on both the top and bottom lines — highlighted investor unease around the pace of recovery and the second-half outlook. While quarterly results demonstrated that operations had stabilized following the cyberattack, the narrowed full-year guidance was perceived as conservative rather than bullish, leaving minimal room for upward revisions. Additionally, with the stock trading near the higher end of its broader range heading into the report, some profit-taking may have amplified the post-earnings move. The decline underscores how, in the current market environment, beating quarterly estimates may not be enough to satisfy expectations when the forward path lacks a clear catalyst for acceleration.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will closely track several factors that could shape Stryker's performance through the remainder of fiscal 2026. The company enters the second half with regained momentum and an elevated order backlog, particularly in its capital equipment business — a segment expected to be a major growth driver in the coming quarters. Management emphasized that there were zero cancellations in the order book, a reassuring signal for demand durability.

One area of focus will be the ongoing recovery from the March cyberattack. While Q2 results showed substantial progress, the full catch-up of deferred revenues is expected to extend through the second half of the year. Any delays or setbacks in this recovery timeline could weigh on investor confidence. The trajectory of adjusted operating margins also warrants attention. The 170-basis-point improvement in Q2 benefited in part from a net tariff benefit; changes in trade policy or supply chain costs could alter that equation.

On the innovation front, the Mako SmartRobotics platform remains a key growth pillar. Stryker reported its best-ever second quarter for Mako installations globally, with systems now deployed in 47 countries and over 2.5 million procedures completed worldwide. The recent launch of the Mako RPS platform for robotic knee surgery could broaden the addressable market. Additionally, procedural volume trends across orthopaedics and MedSurg will serve as a real-time gauge of underlying demand as hospital staffing and capacity constraints continue to normalize. With narrowed guidance and a demanding second-half setup, execution will be paramount.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations